Venetoclax Plus Modified-Intensity Idarubicin and Cytarabine Treatment As First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia

In an open-label, single-arm, multi-center prospective clinical trial, 65 newly diagnosed AML pediatric patients received venetoclax and modified-intensity cytarabine and idarubicin.